缬沙坦合用卡维地洛对充血性心力衰竭心功能及左室重塑的影响
[2]Valle CA, Ignasi CA. Targeting neuronal dysfunction and receptor maging[ J]. Biotechnology, 2007, 16:5-8.
[3]Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure[J]. Eur Heart J, 2001, 22: 1527-1560.
[4]Cohn JN, Tognoni G. Valsartan Heart Failure Trial Investigators. A randomiz ed trial of the angiotensin_receptor blocker valsantan in chronic heart faihm[J ]. N End J Med, 2001, 345(23):1667-1675.
[5]Pfeffer MC, Murray JJ, Velazquez EJ. Valsartan captopril, or both in myocar dial infarction dysfunction, or both. Valsartan in acute myocardial infarction t rial (VALIANT)[J]. N Ensl J Med, 2003, 349:1893-1906.
[6]Ming zh, Weizhong zh, Qide HA, et al. Emerging concept and therapeutic impl ication of_adrenergic receptor subtype signaling[J]. Pharmacology and Therapeu tics， 2005, 108(3):257-268.
[7]Poole_wilsonPA, Swedlberg K, Cleland JG, et al. Comparison of carvedilol an d metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol Emopean trial (COMET): randomized controlled trial[J] . Lancet, 2003, 362(9377):7-13.
[8]Dargie HJ. Effect of earvedilol on outcom after myocardial infarction in pa tients with left_ventrieular dysfunction: the CAPRICORN randomised trial[J]. L ancet, 2001, 357(9266):1385-1390.
注：本文中所涉及到的图表、注解、公式等内容请以PDF格式阅读原文。, 百拇医药(何伟明 卢曙芳 彭 勇 周庆余)
[3]Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure[J]. Eur Heart J, 2001, 22: 1527-1560.
[4]Cohn JN, Tognoni G. Valsartan Heart Failure Trial Investigators. A randomiz ed trial of the angiotensin_receptor blocker valsantan in chronic heart faihm[J ]. N End J Med, 2001, 345(23):1667-1675.
[5]Pfeffer MC, Murray JJ, Velazquez EJ. Valsartan captopril, or both in myocar dial infarction dysfunction, or both. Valsartan in acute myocardial infarction t rial (VALIANT)[J]. N Ensl J Med, 2003, 349:1893-1906.
[6]Ming zh, Weizhong zh, Qide HA, et al. Emerging concept and therapeutic impl ication of_adrenergic receptor subtype signaling[J]. Pharmacology and Therapeu tics， 2005, 108(3):257-268.
[7]Poole_wilsonPA, Swedlberg K, Cleland JG, et al. Comparison of carvedilol an d metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol Emopean trial (COMET): randomized controlled trial[J] . Lancet, 2003, 362(9377):7-13.
[8]Dargie HJ. Effect of earvedilol on outcom after myocardial infarction in pa tients with left_ventrieular dysfunction: the CAPRICORN randomised trial[J]. L ancet, 2001, 357(9266):1385-1390.
注：本文中所涉及到的图表、注解、公式等内容请以PDF格式阅读原文。, 百拇医药(何伟明 卢曙芳 彭 勇 周庆余)
